effect of metoclopramide in pain and nausea

Efficacy of pre-emptive metoclopramide on patients' pain, discomfort and nausea associated with NG Tube insertion

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180717040509N4

Enrollment

Registered

2020-04-02

Start date

2015-09-01

Completion date

Unknown

Last updated

2020-04-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain, nausea and discomfort from nasal-gastric tube insertion.

Interventions

Intervention 1: Intervention group: For the intervention group 15 minutes before NG tube placement, 10 mg metoclopramide (manufactured by Alawi Pharmaceutical Company) will be injected intravenously.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with NG tube Indication

Exclusion criteria

Exclusion criteria: less than 18 years old Lack of consciousness Patients with unstable hemodynamic status (systolic blood pressure less than 90 mmHg) Having a nose bleed Anatomical problems in the nose Traumatic patients Sensitivity to metoclopramide Use of metoclopramide interfering drugs (anticholinergic, digoxin, levodopa, tetracycline) Pregnancy Patients with nausea and vomiting problem NG tube more than twice

Design outcomes

Primary

Measure	Time frame
Pain, nausea and discomfort. Timepoint: 30 and 60 minutes after NG tube insertion. Method of measurement: Visual Analgesic Score.	—

Secondary

Measure	Time frame
Bleeding and vomiting after NG tube insertion. Timepoint: 30 and 60 minutes after NG tube placement. Method of measurement: Visual Analgesic Score.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSeyed Mohammad Hoseininejad

Mazandaran University of Medical Sciences

drhoseininejad@yahoo.com+98 11 3336 1700

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026